Excellence and Innovation for Health-Related Missions

Connect to IMS Health
 
     
 

IMS Headlines:  


10 DEC 2013
Big data company IMS Health looks to own health app prescription opportunity
 
19 JUN 2013
IMS Health Study Identifies $200+ Billion Annual Opportunity from Using Medicines More Responsibly
 
9 MAY 2013
IMS Institute Report Points to Declining Cost Curve for U.S. Medicines in 2012
 
7 APR 2013
IMS Study Examines Impact of States Shifting Patients to Managed Medicaid Plans
 
7 DEC 2012
IMS Government Solutions Signs $3.8 million, 5-year contact with the U.S. Food and Drug Administration
 
7 DEC 2012
- IMS Government Solutions Group signs $395k, 10-month contract with the Office of National Drug Control Policy
 
Read More IMS News


 
     
 

Welcome to the website for IMS Government Solutions, Inc. (IMSGS). IMSGS is a large business based in Fairfax, VA that supports federal agencies in the healthcare arena with professional advisory and assistance services, healthcare data and tools, and evidence-based outcomes research to advance federal missions.

IMSGS is a wholly owned subsidiary of IMS Health, a global leader in medical and pharmaceutical data integration and healthcare consumer analysis. We have supported Government agencies in advancing the modernization, quality and effectiveness of healthcare since the 1970s.

 
   
 
Our Company   |   Contact Us   |   Privacy   |   © 2013 IMS Government Solutions
 
 
 
Close
 
IMS Government Solutions Signs $3.8 million, 5-year contact with the U.S. Food and Drug Administration.
 
7 DEC 2012

IMS Government Solutions today announced its Government Solutions group has signed a $3.8 million, 5-year contact with the U.S. Food and Drug Administration (FDA). Under the terms of the contract, IMS Health will provide the FDA with access to data on pharmaceutical sales that will allow the FDA to respond expeditiously to questions relating to drug safety, the impact of regulatory policies and to potential drug shortage situations.
 
 
Close
 
IMS Government Solutions Group signs $395k, 10-month contract with the Office of National Drug Control Policy
 
7 DEC 2012

IMS Government Solutions today announced the signing of a $395k, 10-month contract with the Office of National Drug Control Policy (ONDCP) for the analysis and magnitude of prescription drug diversion. Under terms of the contract, IMS Government Solutions will provide ONDCP with descriptive and quantitative profiles of commonly diverted prescription drugs, and quantity diverted from the legitimate market either for illicit resale or abuse.
 
 
Close
 
IMS Study Examines Impact of States Shifting Patients to Managed Medicaid Plans
 
Managed Medicaid Supplanting Fee-For-Service Model for Prescriptions; Cost and Quality Goals Yet to be Fully Realized
 
7 APR 2013

Nearly half of all Medicaid prescriptions are now being filled through Managed Medicaid plans, as states switch patients from the Fee-for-Service model in an effort to improve patient care and curb the growth of healthcare costs, according to a new IMS Institute for Healthcare Informatics report. The study, Shift from Fee-for-Service to Managed Medicaid: What is the Impact on Patient Care?, examines prescription drug utilization in four states that have experienced a dramatic shift to Managed Medicaid plans since 2011.

The IMS Institute report, which focuses on Kentucky, New Jersey, New York and Ohio, compares changes in the use of antipsychotic, respiratory and diabetes medications between patients who switched to Managed Medicaid plans and those who remain in Fee-for-Service plans. While early signs indicate that shifting Medicaid beneficiaries to Managed Medicaid programs is affecting some care received by patients, the lack of consistent and measurable change suggests that states’ efforts to bring better care at lower costs to their Medicaid beneficiaries has yet to be fully realized.

"As states take on more responsibility with expanded Medicaid enrollment and management of exchanges in 2014 under the Affordable Care Act, their direct and indirect impact on patient care will be subject to closer scrutiny. Measuring and assessing the consequences of their actions on patient care will become more vital to this critical healthcare program,” says Murray Aitkin, executive director, IMS Institute for Healthcare Informatics.

The full report is available at www.theimsinstitute.org. The study was produced independently as a public service, without industry or government funding.
 
 
Close
 
IMS Health Study Identifies $200+ Billion Annual Opportunity from Using Medicines More Responsibly
 
The IMS Institute has identified $213 billion in costs that are incurred each year in the United States simply because medicines don't get used the correct way.
 
19 JUN 2013

The just released report – Avoidable Costs in U.S. Healthcare: The $200 Billion Opportunity from Using Medicines More Responsibly – examines six areas that contribute to unnecessary costs: medication nonadherence, delayed evidence-based treatment practice, misuse of antibiotics, medication errors, suboptimal use of generics and mismanaged polypharmacy in older adults. Together, these areas lead to unnecessary utilization of healthcare resources involving an estimated 10 million hospital admissions, 78 million outpatient treatments, 246 million prescriptions and four million emergency room visits annually.

The study found significant opportunities for improvement – to ensure that patients receive the right medicines at the right time, and take them in the right way.

The full report is available through our website. An app version for iPads is available in the iTunes store: https://itunes.apple.com/us/app/ims-institute/id625347542

IMS Health is hosting a Webinar to look at the six areas of avoidable costs and discuss what payers and providers can do to identify and address wasteful spending.